7.28
1.62%
-0.12
EDAP TMS S.A. ADR stock is currently priced at $7.28, with a 24-hour trading volume of 63,516.
It has seen a -1.62% decreased in the last 24 hours and a -0.27% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $7.22 pivot point. If it approaches the $7.58 resistance level, significant changes may occur.
Previous Close:
$7.40
Open:
$7.1
24h Volume:
63,516
Market Cap:
$270.12M
Revenue:
$65.36M
Net Income/Loss:
$-22.90M
P/E Ratio:
-14.58
EPS:
-0.4993
Net Cash Flow:
$-20.54M
1W Performance:
+0.28%
1M Performance:
-0.27%
6M Performance:
+6.28%
1Y Performance:
-32.22%
EDAP TMS S.A. ADR Stock (EDAP) Company Profile
Name
EDAP TMS S.A. ADR
Sector
Industry
Phone
33 4 72 15 31 50
Address
Parc d'Activites la Poudrette-Lamartine, 4/6, rue du Dauphiné, Vaulx-en-Velin
EDAP TMS S.A. ADR Stock (EDAP) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Nov-01-22 | Initiated | Jefferies | Buy |
Apr-28-21 | Initiated | Piper Sandler | Overweight |
Apr-15-20 | Initiated | B. Riley FBR | Buy |
Jul-28-14 | Downgrade | Northland Capital | Outperform → Market Perform |
Jun-16-14 | Initiated | H.C. Wainwright | Buy |
Mar-05-13 | Initiated | Northland Capital | Outperform |
Nov-18-10 | Reiterated | Morgan Joseph | Buy |
Aug-20-09 | Reiterated | Roth Capital | Hold |
Nov-24-08 | Reiterated | Roth Capital | Hold |
Mar-26-08 | Reiterated | Roth Capital | Hold |
Nov-09-07 | Reiterated | Roth Capital | Hold |
Mar-16-07 | Reiterated | Roth Capital | Hold |
Jan-24-07 | Reiterated | Roth Capital | Hold |
View All
EDAP TMS S.A. ADR Stock (EDAP) Latest News
EDAP to Present at the Oppenheimer 34th Annual Healthcare MedTech & Services Conference
GlobeNewswire Inc.
EDAP Announces Preliminary Fourth Quarter Record Focal One® System Sales and Placements
GlobeNewswire Inc.
EDAP Appoints Ken Mobeck, Global Chief Financial Officer, and Francois Dietsch, Global Chief Accounting Officer
GlobeNewswire Inc.
EDAP Appoints Lance Willsey, M.S., M.D. to Board of Directors
GlobeNewswire Inc.
EDAP Announces Third Quarter 2023 Financial Results
GlobeNewswire Inc.
EDAP to Present at the Jefferies London Healthcare Conference
GlobeNewswire Inc.
EDAP TMS S.A. ADR Stock (EDAP) Financials Data
EDAP TMS S.A. ADR (EDAP) Revenue 2024
EDAP reported a revenue (TTM) of $65.36 million for the quarter ending December 31, 2023, a +12.57% rise year-over-year.
EDAP TMS S.A. ADR (EDAP) Net Income 2024
EDAP net income (TTM) was -$22.90 million for the quarter ending December 31, 2023, a -693.45% decrease year-over-year.
EDAP TMS S.A. ADR (EDAP) Cash Flow 2024
EDAP recorded a free cash flow (TTM) of -$20.54 million for the quarter ending December 31, 2023, a -264.48% decrease year-over-year.
EDAP TMS S.A. ADR (EDAP) Earnings per Share 2024
EDAP earnings per share (TTM) was -$0.6163 for the quarter ending December 31, 2023, a -687.10% decline year-over-year.
About EDAP TMS S.A. ADR
EDAP TMS S.A., together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally-invasive medical devices for the treatment of urological diseases worldwide. The company operates in two divisions: High Intensity Focused Ultrasound (HIFU), and Urology Devices and Services (UDS). The HIFU division develops, manufactures, and markets devices for the minimally invasive destruction of various types of localized tumors using HIFU technology. It offers Ablatherm, a HIFU device for the treatment of organ-confined prostate cancer, referred to as T1-T2 stage; and Focal One device, a HIFU robotic device for the focal therapy of localized prostate cancer. This division also leases equipment; sells consumables; and offers treatment related services and maintenance services. The UDS division develops, manufactures, markets, and services medical devices for the minimally invasive diagnosis or treatment of urological disorders, primarily urinary stones and other clinical indications. It offers lithotripters, such as Sonolith i-move and Sonolith i-sys for the treatment of urinary tract stones by means of extracorporeal shockwave lithotripsy technology. This division also leases lithotripters; sells disposables and spare parts; and provides maintenance services. The company markets and sells its products through its direct marketing and sales organization, as well as through third-party distributors and agents. Its customers include public and private hospitals, urology clinics, and research institutions. The company was founded in 1979 and is headquartered in Vaulx-en-Velin, France.
Cap:
|
Volume (24h):